Molecular Partners Expands Radio-DARPin Collaboration

Molecular Partners (MOLN) has released an update.

Molecular Partners and Orano Med have expanded their co-development agreement to create four Radio-DARPin programs, with each company securing commercialization rights to two. The strengthened collaboration aims at advancing targeted cancer therapies, with first-in-human studies expected to begin in 2025. Despite the expansion, Molecular Partners anticipates no immediate financial impact for 2024 and maintains a strong cash position.

For further insights into MOLN stock, check out TipRanks’ Stock Analysis page.